Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

by NASDAQ Market News November 18, 2021

NASDAQ Market News
Click here to email author

Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism

GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH

Ads